Description

This biotechnology company is focused on developing novel therapies for heart failure. The company is using stem cell technology and a patient Biobank licensed from a top ten University to generate human heart cell disease models to accelerate drug discovery and development. To date the company has generated USD 1.75 million in revenue from pharmaceutical companies, the USFDA and grants. It has also progressed its first product candidate into animal trials.

Posted Oct 18, 2016

Did you know that social networking is a great way to buy a business? Sign up now and we'll show you how.

By clicking "Sign Up" you confirm that you accept the Terms of Use and Privacy Policy, including cookie use.

Disclaimer: MergerNetwork has not independently verified any of the information in this listing and makes no warranty as to its accuracy or completeness.